Zoom meeting 09/30/2020

Attendees: Brenda, Maurice, Iris, Tomoyuki, JB

1) Jana Stojanova is a new member of the PMx committee (she did not attend the meeting due to misunderstood of the time schedule), she will briefly introduce herself next meeting

2) Workshop Rome proposal
   a. Symposium: Optimal sampling strategies for TDM. On behalf of the pharmacometrics committee. This workshop is very interesting and has to be resubmitted. Iris and Sebastian will try to rewrite the proposal to make it more attractive by including practical example (focus on vancomycin).
   b. Symposium oncology: the proposal is quite technical (QSPR) and perhaps more dedicated to PAGE than IATDMCT public, it has to be modified in a more practical way. Additionally, a session on TDM in oncology pro and contra has been presented in Banff, it is probably not the priority for Rome.
   c. PMx and biologicals: it correspond exactly to the program of Rome: “The program will therefore be focused on the process of using concentrations of drugs, on the principles of pharmacokinetic and on the pharmacodynamic relationships, in order to optimize therapy in individual patients. Particular attention will be paid to the following topics: therapeutics proteins, Individualisation in pediatry”. This symposium proposal will be resubmitted.

You can also propose another topic or idea in the Google Doc: https://docs.google.com/document/d/1DvHXw7BqGKrblOnXVFQxykdrVQSRrPRHemhAU_g9K4/edit?usp=sharing

3) Iris, Maurice and Brenda wrote an article for COMPASS “The use of pharmacometric models for COVID-19 treatment”. They would like to publish a full version in TDM entitled “Benefits and opportunities of pharmacometrics for the IATDMCT community”, the goal is to present the approach and give some new ideas to other IATDMCT members. Following that, they proposed to write very practical articles or tutorials on 3 topics for TDM
   a. How to make the most of available clinical data
   b. How to use an available model to plan future studies to get out the most conclusive results possible?
   c. How to use an already available model for TDM?

The detail of the content is attach with this minute. Members of the PMx committee are invited to participate to one of these practical article (you can choose the one that inspire you the most), the goal is to make working groups and if possible to have articles ready for the next Rome congress in September 2021. The idea would be to propose a pre-conference for Rome dealing with these topics and in the same time to propose a special PMx issue in TDM with these articles.

4) JB had a lot of positive answer to participate to the article about the graduation of exposure/effect studies proposed to clinPK. However, JB explain his doubt about the ability to succeed in this article due to the difference in variable of interest in different fields (immunosuppressant, oncology, antibiotics...). He explains that he began to collect some important information by taking a practical example (as sample size of the study, validation or not, method used and results conforms to what is mechanistically expected) but he said
that the tables in reviews are quite heterogeneous depending on the topic and it is not as simple as initially expected. Some new ideas or suggestions would be good! Otherwise, JB wants to write to the ClinPK editor to explain the problems and cancel his proposal.

5) Next COMPASS issue: we have to think about an article from PMx committee for the next COMPASS issue. It can be a PhD student works or a summary of an interesting article recently published or any other ideas.